PRIMA: Primary Mesh Closure of Abdominal Midline Wounds

Sponsor
Erasmus Medical Center (Other)
Overall Status
Completed
CT.gov ID
NCT00761475
Collaborator
Baxter Healthcare Corporation (Industry), Aesculap AG (Industry)
480
12
3
73.9
40
0.5

Study Details

Study Description

Brief Summary

Incisional hernia is the most frequently seen long term complication in surgery causing much morbidity and even mortality in patients. Despite studies on the optimal closing technique for laparotomies, the risk for incisional hernia after midline incision remains about 5-20 %. Major risk factors for incisional hernia after a laparotomy, like obesity, steroid use, malnutrition, smoking and connective tissue disorders, are known. Despite this knowledge, there has not yet been developed a sufficient method for prevention. One specific group of high risk patients are patients with an abdominal aortic aneurysm (AAA). The relationship between aortic aneurysm and other abdominal wall hernias, like inguinal hernias, has been reported. Retrospective and prospective studies have shown an average risk for incisional hernia after AAA repair of 31.6 %. Another high risk group is the group of obese patients. Patients with a BMI of more than 27 have a high risk of developing an incisional hernia after midline incision with an incidence of 22% after 12 months. Considering only 50 % of incisional hernia will be clinically evident in the first 12 months, the total incidence will be above 30%. This high risk group of patients with obesitas and aneurysmatic disease can benefit most from prevention. Some small studies have been performed to evaluate the usefulness and safety of primary laparotomy wound closure with the aid of prosthetic mesh. These studies show a very low risk for incisional hernias and a low infection rate, even when used in contaminated wounds such as colostomal surgery. However, there has not been performed an adequate randomized controlled trial to study the prevention of incisional hernias. Our hypothesis is that incisional hernia prevention with use of prosthetic mesh after laparotomy is effective in patients with aortic aneurysm and in obese patients with a BMI of more than 27.

Condition or Disease Intervention/Treatment Phase
  • Procedure: mesh supported closure
  • Procedure: primary closure
  • Procedure: mesh supported closure
Phase 3

Study Design

Study Type:
Interventional
Actual Enrollment :
480 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Primary Mesh Closure of Abdominal Midline Wounds; a Prospective Randomized Multicenter Trial
Study Start Date :
Feb 1, 2009
Actual Primary Completion Date :
Dec 1, 2012
Actual Study Completion Date :
Apr 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: 1

primary closure of the midline

Procedure: primary closure
primary closure of the midline

Active Comparator: 2

onlay mesh supported closure

Procedure: mesh supported closure
onlay mesh supported closure midline laparotomy

Active Comparator: 3

sublay mesh supported closure

Procedure: mesh supported closure
sublay mesh supported closure midline laparotomy

Outcome Measures

Primary Outcome Measures

  1. incisional hernia occurence [2 years]

Secondary Outcome Measures

  1. complications [1 month]

  2. post-operative pain [1 month]

  3. quality of life [2 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Every elective midline laparotomy for patients with Abdominal Aortic Aneurysm and patients with a BMI of more than 27.

  • Signed informed consent

Exclusion Criteria:
  • Age < 18 years

  • Emergency procedure

  • Inclusion in other trials

  • Aortic reconstruction for obstructive disease

  • Life expectancy less than 24 months

  • Pregnant women

Contacts and Locations

Locations

Site City State Country Postal Code
1 Wilhelminenspital Vienna Austria
2 Berlin-Charite Universitatsklinikum Berlin Germany
3 Hamburg-Eppefdorf Universitatsklinikum Hamburg Germany
4 Heidelberg University Medical Center Heidelberg Germany
5 Munchen University Medical Center Munchen Germany
6 Erasmus Medical Center Rotterdam Zuid-Holland Netherlands 3015 CE
7 IJsselland Ziekenhuis Capelle a/d IJssel Netherlands
8 Scheper Ziekenhuis Emmen Netherlands
9 Maasstad Ziekenhuis Rotterdam Netherlands
10 Sint Franciscus Gasthuis Rotterdam Netherlands
11 Maxima Medisch Centrum Veldhoven Netherlands
12 Isala klinieken Zwolle Netherlands

Sponsors and Collaborators

  • Erasmus Medical Center
  • Baxter Healthcare Corporation
  • Aesculap AG

Investigators

  • Principal Investigator: J.F. Lange, Professor, Erasmus Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hasan Eker, Prof. Dr. J.F. Lange, Erasmus Medical Center
ClinicalTrials.gov Identifier:
NCT00761475
Other Study ID Numbers:
  • PRIMA TRIAL
First Posted:
Sep 29, 2008
Last Update Posted:
Oct 28, 2016
Last Verified:
Oct 1, 2016
Keywords provided by Hasan Eker, Prof. Dr. J.F. Lange, Erasmus Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 28, 2016